Cure My Disease

Don't miss your cure!

 Log in / Sign up

Needle under the skin: easier nivolumab shot studied for advanced tumors

NCT ID NCT03656718

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects. 139 participants took part, and the results help doctors understand if this easier method works as well as the standard IV infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer hepatocellular carcinoma melanoma metastatic melanoma Neoplasms by Site non-small cell lung carcinoma renal cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS BY SITE

Contacts and locations

Locations

  • Greenville Health System

    Greenville, South Carolina, 29605, United States

  • Local Institution - 0001

    Charlotte, North Carolina, 28204, United States

  • Local Institution - 0003

    Rozzano, MI, 20089, Italy

  • Local Institution - 0004

    Padova, 35128, Italy

  • Local Institution - 0005

    Santiago, 0, Chile

  • Local Institution - 0007

    Dallas, Texas, 75246, United States

  • Local Institution - 0009

    Beaumont, Texas, 77702-1449, United States

  • Local Institution - 0010

    Austin, Texas, 78705, United States

  • Local Institution - 0011

    Tyler, Texas, 75702, United States

  • Local Institution - 0012

    Eugene, Oregon, 97401, United States

  • Local Institution - 0014

    Dunedin, 9012, New Zealand

  • Local Institution - 0015

    Tauranga, 3112, New Zealand

  • Local Institution - 0016

    Málaga, 29010, Spain

  • Local Institution - 0017

    Madrid, 28007, Spain

  • Local Institution - 0018

    Newtown, Wellington Region, 6021, New Zealand

  • Local Institution - 0019

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Local Institution - 0020

    Detroit, Michigan, 48201-2014, United States

  • Local Institution - 0021

    Villejuif, 94805, France

  • Local Institution - 0022

    Saint-Herblain, 44805, France

  • Local Institution - 0024

    Rockville, Maryland, 20850, United States

  • Local Institution - 0025

    CABA, 1426, Argentina

  • Local Institution - 0026

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Local Institution - 0031

    Liverpool, L7 8YA, United Kingdom

  • Local Institution - 0033

    Cardiff, Glamorgan, CF14 2TL, United Kingdom

  • Local Institution - 0035

    CABA, 1199, Argentina

  • Local Institution - 0037

    São Paulo, 05651-901, Brazil

  • Local Institution - 0038

    Porto Alegre, Rio Grande do Sul, 90610000, Brazil

  • Local Institution - 0039

    Maastricht, 6229 HX, Netherlands

  • Local Institution - 0040

    Rotorua, Bay of Plenty, 3046, New Zealand

  • Local Institution - 0045

    Querétaro, 76000, Mexico

  • Local Institution - 0046

    Monterrey, Nuevo León, 64710, Mexico

  • Local Institution - 0047

    Monterrey, Nuevo León, 66460, Mexico

  • Local Institution - 0048

    Mexico City, Mexico City, 14080, Mexico

  • Local Institution - 0049

    Puebla City, 72424, Mexico

  • Local Institution - 0050

    Mexico City, Mexico City, 03100, Mexico

  • Winship Cancer Institute.

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.